Prelude Therapeutics Incorporated
News
Prelude Therapeutics (NASDAQ:PRLD) Stock Rating Reaffirmed by HC Wainwright
Ticker Report Prelude Therapeutics (NASDAQ:PRLD - Get Free Report)s stock had its "neutral" rating restated by stock analysts at HC Wainwright in a research report issued on Tuesday, Benzinga reports. They...\n more…
Prelude Therapeutics (NASDAQ:PRLD) Trading Up 2.3%
Ticker Report Prelude Therapeutics Incorporated (NASDAQ:PRLD - Get Free Report) shares were up 2.3% during mid-day trading on Monday . The stock traded as high as $5.03 and last traded at $4.96. Approximately...\n more…
Prelude Therapeutics Announces Publication of Abstract for Presentation at the European Society of Medical Oncology (ESMO) Congress 2024
Globe Newswire PRT3789, a novel, highly-selective SMARCA2 degrader in patients with advanced solid tumors with a SMARCA4 mutation oral session presentation: September 13, 2024, 4:00 PM CEST (10:00 AM EST...\n more…
Q3 2024 EPS Estimates for Prelude Therapeutics Incorporated (NASDAQ:PRLD) Lowered by Analyst
Ticker Report Prelude Therapeutics Incorporated (NASDAQ:PRLD - Free Report) - Stock analysts at HC Wainwright reduced their Q3 2024 EPS estimates for shares of Prelude Therapeutics in a research note issued on...\n more…
Prelude Therapeutics Incorporated (NASDAQ:PRLD) to Post Q1 2025 Earnings of ($0.49) Per Share, HC Wainwright Forecasts
Zolmax Prelude Therapeutics Incorporated (NASDAQ:PRLD - Free Report) - Stock analysts at HC Wainwright issued their Q1 2025 earnings per share estimates for Prelude Therapeutics in a research note issued...\n more…